PHAT
Phathom Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$938.07M
P/E Ratio
—
EPS
$-3.03
Beta
0.61
52W High
$18.31
52W Low
$2.21
50-Day MA
$11.83
200-Day MA
$12.29
Dividend Yield
—
Profit Margin
-126.40%
Forward P/E
—
PEG Ratio
—
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
Fundamentals
| Revenue (TTM) | $175.11M |
| Gross Profit (TTM) | $152.51M |
| EBITDA | $-159.35M |
| Operating Margin | -10.30% |
| Return on Equity | -3489.00% |
| Return on Assets | -31.40% |
| Revenue/Share (TTM) | $2.40 |
| Book Value | $-6.13 |
| Price-to-Book | 25.37 |
| Price-to-Sales (TTM) | 5.36 |
| EV/Revenue | 5.57 |
| EV/EBITDA | -2.20 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 94.10% |
| Shares Outstanding | $79.43M |
| Float | $59.23M |
| % Insiders | 4.58% |
| % Institutions | 83.17% |
Analyst Ratings
Consensus ($23.70 target)
2
Strong Buy8
Buy1
HoldData last updated: 4/9/2026